- Oncology franchise continues to stand out
- Increased opex is a reflection of R&D investment
The controversy that surrounded the rollout of the AstraZeneca (AZN) Covid-19 vaccine now seems like a distant memory. The company has updated its revenue guidance for the year after several of its products, including the Covid-19 prevention drug Evusheld, exceeded sales expectations in the first half.